Afatinib‐induced toxic epidermal necrolysis: A case report with a literature review

We present a 70‐year‐old female patient diagnosed with epidermal growth factor receptor‐mutated metastatic non‐small cell lung cancer (T4N2M1a), who developed afatinib‐induced toxic epidermal necrolysis (TEN). We have also performed a PubMed/Medline literature review to detect other possible cases o...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2024-08, Vol.90 (8), p.2030-2033
Main Authors: Belančić, Andrej, Hlača, Nika, Peternel, Sandra, Golčić, Marin, Prpić‐Massari, Larisa, Vlahović‐Palčevski, Vera
Format: Article
Language:English
Subjects:
afatinib
Afatinib - adverse effects
Afatinib - therapeutic use
Aged
Antineoplastic Agents - adverse effects
Carcinoma, Non-Small-Cell Lung - drug therapy
Cyclosporine - adverse effects
Cyclosporine - therapeutic use
ErbB Receptors - antagonists & inhibitors
ErbB Receptors - genetics
Female
Humans
Lung Neoplasms - drug therapy
pharmacovigilance
Quinazolines - adverse effects
Quinazolines - therapeutic use
serious adverse drug reaction
Stevens-Johnson Syndrome - drug therapy
Stevens-Johnson Syndrome - etiology
toxic epidermal necrolysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present a 70‐year‐old female patient diagnosed with epidermal growth factor receptor‐mutated metastatic non‐small cell lung cancer (T4N2M1a), who developed afatinib‐induced toxic epidermal necrolysis (TEN). We have also performed a PubMed/Medline literature review to detect other possible cases of TEN/Stevens–Johnson syndrome associated with afatinib treatment and found only 5 other cases reported. To our best knowledge, this is the first case of afatinib‐induced TEN successfully treated with cyclosporine.
ISSN:0306-5251
1365-2125
1365-2125
DOI:10.1111/bcp.16114